Mycophenolate mofetil

Lancet

Volumn 348, Issue 9038, 1996, Pages 1357-1359

  Lipsky, James J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTACID AGENT; AZATHIOPRINE; COLESTYRAMINE; CYCLOSPORIN; FUROSEMIDE; INOSINATE DEHYDROGENASE; MAGNESIUM HYDROXIDE; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SALICYLIC ACID;

ABDOMINAL CRAMP; ANEMIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS;

EID: 0030590745     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)10310-X     Document Type: Article

References (28)

1. Gray DWR. Mycophenolate mofetil for transplantation: new drug, old problems? Lancet. 346:1995;390.
2. Florey HW, Gilliver K, Jennings MA, Sanders AG. Mycophenolic acid: an antibiotic from Penicillium brevicompactum Dierckx. Lancet. 1:1946;46-49.
3. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer. 57:1994;568-573.
4. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol. 11:1993;S117-19.
5. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. J Am Acad Dermatol. 17:1987;962-971.
6. Allison AC, Eugui EM. Immunsuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 136:1993;5-28.
7. Catapano CV, Dayton JS, Mitchell BS, Fernandes DJ. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Mol Pharmacol. 47:1995;948-955.
8. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 268:1993;27286-27290.
9. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 10:1996;77-84.
10. Morris RE. Mechanisms of action of new immunosuppressive drugs. Ther Drug Monit. 17:1995;564-569.
11. Nagy SE, Andersson JP, Andersson UG. Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines. Immunopharmacology. 26:1993;11-20.
12. Mulkins MA, Ng M, Lewis RA. Mycophenolic acid inhibits the degranulation of rat peritoneal mast cells. Cell Immunol. 141:1992;508-517.
13. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 36:1996;315-324.
14. Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (rs61443) - a short review. Transplant Proc. 28:1996;925-929.
15. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation. 53:1992;428-432.
16. Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem. 41:1995;295-299.
17. Langman LJ, Shapiro AMJ, Lakey JRT, LeGatt DF, Kneteman NM, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immnuosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model. Transplantation. 61:1996;87-92.
18. Franklin TJ, Morris WP. Phramacodynamics of the inhibition of GTP synthesis in vitro by mycophenolic acid. Adv Enzyme Regul. 34:1994;107-117.
19. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-25.
20. Sollinger HW. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 60:1995;225-232.
21. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-37.
22. Deierhoi MH, Kauffman RS, Hudson SL, et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg. 217:1993;476-484.
23. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722-29.
24. Kirklin JK, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant. 13:1994;444-450.
25. Taylor DO, Ensley D, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant. 13:1994;571-582.
26. Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit. 17:1995;685-689.
27. Shaw LM, Sollinger HW, Halloran P, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit. 17:1995;690-699.
28. Mitchell BS, Dayton JS, Turka LA, Thompson CG. IMP dehydrogenase inhibitors as immunomodulators. Ann N Y Acad Sci. 685:1993;217-224.